Avonex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The avonex market size has grown strongly in recent years. It will grow from $1.95 million in 2025 to $2.07 million in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to early approval of interferon beta therapies, rising ms diagnosis rates, limited oral ms options historically, established safety profile, neurologist familiarity with interferons.

The avonex market size is expected to see strong growth in the next few years. It will grow to $2.58 million in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to expansion of ms patient population, demand for stable long-term therapies, growth in specialty neurology clinics, improved injection devices, continued reimbursement support. Major trends in the forecast period include sustained use of interferon therapies in ms, shift toward long-term disease modifying treatments, growing preference for weekly injectable regimens, focus on early multiple sclerosis intervention, increased patient adherence support programs.

The increasing prevalence of multiple sclerosis (MS) is expected to propel the growth of the Avonex market going forward. Multiple sclerosis is a chronic autoimmune disorder in which the immune system attacks the protective myelin sheath surrounding nerve fibers in the central nervous system, disrupting communication between the brain and the body. The rise in MS cases is attributed to improved diagnostic capabilities, environmental influences such as vitamin D deficiency, genetic susceptibility, and changes in lifestyle and migration patterns. Avonex is used in the management of multiple sclerosis as it helps reduce inflammation, lower relapse frequency, and slow the progression of physical disability by modulating immune system activity. For instance, in May 2024, according to a report published by the Multiple Sclerosis Trust, a UK-based charity, a recent study found that the number of people living with multiple sclerosis in the UK increased by nearly 13% by 2024, including a 15% rise in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. Therefore, the growing prevalence of multiple sclerosis is driving the expansion of the Avonex market.

Major companies operating in the Avonex (interferon beta-1a) market are emphasizing label expansion strategies, such as pregnancy-safe formulations, to strengthen their competitive position. Pregnancy-safe formulations are designed to be used during pregnancy without posing risks to the mother or the developing fetus. For instance, in February 2024, Biogen Inc., a US-based biotechnology company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Avonex and peginterferon beta-1a, allowing their use during pregnancy and breastfeeding after clinical data demonstrated no increased risk of congenital abnormalities. This regulatory development broadens the eligible patient population and reinforces Avonex’s long-term market relevance. However, the product continues to face pricing and margin pressures as key originator patents have expired in several regions, increasing exposure to biosimilar competition.

In November 2024, Vanguard Group Inc., a US-based investment firm, acquired shares in Biogen Inc. for an undisclosed amount. This investment reflects Vanguard’s strategy to diversify and strengthen its portfolio while demonstrating confidence in Biogen’s growth prospects and innovative product pipeline. Biogen Inc. is a US-based company engaged in the manufacturing of Avonex.

Major companies operating in the avonex market are Biogen Inc.

North America was the largest region in the avonex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the avonex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the avonex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the avonex market by increasing costs for imported biologic ingredients, prefilled syringe components, and cold-chain transportation. These impacts are more visible in regions reliant on cross-border supply, including asia pacific and latin america. Hospital and retail pharmacy pricing structures have faced margin pressure. However, tariffs have encouraged regional filling and packaging operations. This supports supply continuity and reduces dependency on international logistics over time.

The avonex market research report is one of a series of new reports that provides avonex market statistics, including avonex industry global market size, regional shares, competitors with a avonex market share, detailed avonex market segments, market trends and opportunities, and any further data you may need to thrive in the avonex industry. This avonex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Avonex is the brand name for interferon beta-1a, a medication primarily used to treat relapsing forms of multiple sclerosis (MS). It helps lower the frequency of MS relapses and slow the progression of physical disability. Avonex acts as an immunomodulator by altering immune system activity, thereby reducing inflammation and nerve damage associated with multiple sclerosis.

The main forms of Avonex include prefilled syringes and powder formulations. Prefilled syringes are single-dose, ready-to-use containers that come prefilled with medication and fitted with a needle, offering convenience and ease of administration. The clinical indications include relapsing forms of multiple sclerosis (RMS), clinically isolated syndrome (CIS), reduction of relapse rates in MS, slowing of disability progression, long-term disease management, and early-stage MS treatment. Avonex is distributed through channels such as wholesalers, retail pharmacies, and direct-to-patient sales and is used across applications including hospitals, drug stores, and other healthcare settings.

The avonex market consists of sales of monoclonal antibodies, spinal muscular atrophy medications, biosimilars and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.